Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
You may also be interested in...
As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.